-- Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.9%.
The iShares Biotechnology ETF (IBB) decreased 0.4%.
In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and lowered its price target to $15 from $57. Janux shares were down 3%.